Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company whose news flow is closely tied to the development of its two lead small molecule drug candidates, enobosarm and sabizabulin. Company press releases emphasize cardiometabolic and inflammatory diseases, with a particular focus on obesity, chronic weight management, and inflammation in atherosclerotic cardiovascular disease.
Much of Veru’s recent news has centered on enobosarm, a selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP-1 receptor agonist (GLP-1 RA) drugs more tissue selective for fat loss while preserving lean mass and physical function. Updates include topline efficacy and safety data from the Phase 2b QUALITY study and its Maintenance Extension, which evaluated enobosarm in older patients receiving semaglutide for weight reduction. The company has reported that enobosarm plus semaglutide preserved lean mass, increased fat loss, and reduced declines in stair climb power compared to placebo plus semaglutide, as well as reduced weight and fat regain after semaglutide discontinuation.
Investors following VERU news will also see announcements about regulatory interactions and trial design. Veru has disclosed a successful FDA meeting that, according to the company, provided regulatory clarity for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, including guidance that incremental weight loss can serve as an acceptable primary endpoint and confirmation of the 3 mg dose for future development. News releases describe the planned Phase 2b PLATEAU study, designed to evaluate enobosarm 3 mg in patients with obesity initiating GLP-1 RA treatment, with endpoints focused on total body weight, body composition, and physical function.
Additional VERU headlines cover capital markets activity and corporate actions, such as an underwritten public offering to fund enobosarm development, a 1-for-10 reverse stock split, and Nasdaq notifications regarding minimum bid price compliance. Conference presentations at scientific meetings, collaborations on a modified release enobosarm formulation using Laxxon Medical’s SPID-Technology, and periodic financial results also feature prominently in the company’s news stream.
For investors and observers, the Veru news page provides a consolidated view of clinical trial milestones, FDA-related updates, financing transactions, and scientific presentations that shape the outlook for VERU’s cardiometabolic and inflammatory disease programs.
Veru Inc. (NASDAQ: VERU) reported positive results from its Phase 2b QUALITY study evaluating enobosarm in combination with semaglutide for weight loss management. The study showed that enobosarm 3mg + semaglutide achieved 100% preservation of lean mass compared to placebo + semaglutide at 16 weeks (p<0.001). The combination resulted in 100% fat mass loss versus 66% for placebo + semaglutide.
In the Maintenance Extension study, enobosarm 3mg reduced body weight regain by 46% after semaglutide discontinuation. The company also announced a novel modified release oral enobosarm formulation with patent protection through 2046. For Q3 2025, Veru reported reduced operating losses of $7.5 million compared to $10.5 million year-over-year, with cash reserves of $15.0 million as of June 30, 2025.
Veru Inc. (NASDAQ: VERU) has achieved a significant milestone in drug development by selecting a novel modified-release oral formulation of enobosarm using Laxxon Medical's proprietary SPID® (Screen Printing Innovation Drug)-Technology.
The new tablet formulation demonstrated successful target release profiles, including reduced maximum plasma concentration (Cmax), delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and similar absorption extent compared to immediate release capsules.
This development marks a crucial step as Veru advances towards Phase 3 clinical trials and potential commercialization of enobosarm, pending regulatory approval.
Veru Inc. (NASDAQ: VERU) has successfully developed a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator targeted for chronic weight loss management. The company completed a single dose, open label pilot study that confirmed the desired pharmacokinetic profile of the new 3mg formulation.
The study demonstrated key improvements including reduced maximum plasma concentration, delayed time to maximum plasma concentration, and a distinct secondary peak plasma concentration, while maintaining similar absorption compared to immediate release capsules. The formulation, developed in partnership with Laxxon Medical using SPID®-Technology, is protected by patents through 2037, with new patent applications potentially extending protection until 2046.
Veru (NASDAQ: VERU) has announced a 1-for-10 reverse stock split effective August 8, 2025, with split-adjusted trading beginning August 11, 2025. The reverse split aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
The split, approved by shareholders on July 25, 2025, will consolidate every 10 shares into one share, maintaining the $0.01 par value. No fractional shares will be issued, with cash payments provided instead. The company's transfer agent, Computershare, will manage the exchange process, with shareholders receiving instructions for surrendering pre-split certificates.
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, will host a conference call and webcast to discuss its fiscal 2025 third quarter financial results on Tuesday, August 12, 2025, at 8:00 a.m. ET.
The event will be accessible via webcast on the company's website at www.verupharma.com. Investors can join by phone at 1-800-341-1602 (domestic) or 1-412-902-6706 (international). A replay will be available online for three months and by phone for one week.
Veru (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, has announced its participation in the 2025 BTIG Virtual Biotech Conference. The company will engage in one-on-one meetings and deliver a fireside chat presentation to investors during the conference, which is scheduled for July 29-30, 2025.
Veru (NASDAQ:VERU) announced positive results from their Phase 2b QUALITY and Maintenance Extension Study for enobosarm, a treatment aimed at preventing weight regain after discontinuing semaglutide (GLP-1 receptor agonist).
The study showed that while the placebo group regained 43% of lost body weight after stopping semaglutide, enobosarm 3mg reduced weight regain by 46% and completely prevented fat regain. The enobosarm groups demonstrated up to 93% greater fat loss and 100% lean mass preservation compared to placebo.
Based on these positive results, Veru will advance enobosarm 3mg to Phase 3 clinical trials and has secured an FDA meeting to discuss the program. The drug showed a favorable safety profile with minimal gastrointestinal side effects during the maintenance period.
Veru Inc. (NASDAQ: VERU) has released a Virtual Investor KOL segment featuring obesity expert Louis J. Aronne, MD, FACP. The segment includes a discussion between Dr. Aronne and Veru's President, CEO, and Founder, Mitchell Steiner, M.D., F.A.C.S, focusing on obesity and GLP-1s, current treatment landscape, and unmet needs in the field. The discussion also highlights Veru's lead program, the Enobosarm Phase 2b QUALITY study, and reviews the company's latest topline clinical data.